Aravive Inc

Aravive — Investor Presentation (October 2021)

37 slides from Aravive's investor presentation, Oct 28, 2021

  1. Slide 1: Halting Disease Progression in its Tracks

    ¢°9 aravive Halting Corporate Presentation Disease October 2021 Progression : ARAV (NASDAQ) in its Tracks hg © 2021 Aravive, inc. in

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that may discuss Aravive's plans, goals, intentions and expectations as to future trends, events, results of operations, financial condition or other matters. Forward: looking statements generally include statements tha

  3. Slide 3: Developing Transformative, Targeted Cancer Therapeutics

    Developing Transformative, Targeted Cancer Therapeutics Batiraxcept (AVB-500): Differentiated Approach to Specific Inhibition of GAS6/AXL Signaling Pathway Registrational Phase 3 Trial in PROC Ongoing Phase 1b trial demonstrated more than doubling of progression-free survival than SOC in target popu

  4. Slide 4: GAS6/AXL Signaling Pathway

    GAS6/AXL Signaling Pathway Drives Activation, Migration and Invasion of Abnormal Cells Causes immune ‘Suppression Drives Resistance to Chemotherapy Radatherapy, Targeted Therapy, etc Drives Resistanceto 4 Apoptosis/Autophagy Leadsto EMT ang Profferaton Metastasis GAS6: Sole Ligand for AXLand no Liga

  5. Slide 5: Batiraxcept: High Affinity, Highly Specific GAS6/AXL Inhibitor

    Batiraxcept: High Affinity, Highly Specific GAS6/AXL Inhibitor Modified AXL-Fc fusion protein engineered for strong stability and very high affinity for GAS6 * ~200 fold greater affinity for human GAS6 compared to native AXL receptor * Preclinical data demonstrated relationship between affinity and

  6. Slide 6: Batiraxcept: Addresses Limitations of Other Therapies

    Batiraxcept: Addresses Limitations of Other Therapies As an engineered decoy receptor with 200-fold PANY TAGE) rarcer SELECTIVE higher affinity for GAS6 versus natural EORANE GAS6I/AXL interaction, batiraxcept provides Aravive batiraxcept (Ph 3) Gas6 Yes potent & selective inhibition of this signali

  7. Slide 7: Clinical Pipeline

    Clinical Pipeline Potential Opportunities for Expansion in Additional Indications and Drug Combinations Indication Preclinical Batiraxcept (AVB-500) ‘OVARIAN CANCER CLEAR CELL RENAL CANCER PANCREATIC ADENOCARCINOMA, Batiraxcept investigator Sponsored Trials OVARIAN CANCER Bispecific Antibodies (Canc

  8. Slide 8: Lead Program: Batiraxcept in Platinum Resistant Ovarian Cancer (PROC)

    Lead Program: Batiraxcept in Platinum Resistant Ovarian Cancer (PROC); Patients Have Advanced Disease and High Mortality th LEADING CAUSE OF DEATH 5 among women in the U.S. NEW CASES ~21 ,400 and ~13,800 deaths expected in the U.S. in 2021 Ovarian Cancer i) ~31 4, 000 and ~207,300 deaths worldwide i

  9. Slide 9: Phase 1a and 1b PK/PD Summary Data in PROC

    Phase 1a and 1b PK/PD Summary Data in PROC Batiraxcept q14 days Pegylated liposomal doxorubicin (PLD) 40 mg/m? di of 28-day cycle; Paclitaxel (PAC) 80 mg/m? day 1, day 8, day 15 of 28-day cycle; Maintenance dosing on batiraxcept monotherapy IDMC Review IDMC Review [%) 84 subjects, including 31 healt

  10. Slide 10: Batiraxcept/Paclitaxel Combination Clinical Activity in Subgroups

    Batiraxcept/ Paclitaxel Combination Clinical Activity in Subgroups Paclitaxel Alone Provides 13-22% ORR, 2.8-4.4 months PFS, and 10.7-13.1 mOS* EFFICACY DATA FOR PATIENTS RECEIVING 10MGIKG AND 15MGIKG OF BATIRAXCEPT & PACLITAXEL INCLUDING IF BEVACIZUMAB NAIVE OR PREVIOUSLY RECEIVED BEVACIZUMAB >MEC"

  11. Slide 11: Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients

    Time on Treatment and Depth of Response for Batiraxcept + Paclitaxel Patients (10 and 15mg/kg groups) 96% were on 3"+ Line of Therapy; 85% of Patients on their 3" Line of Therapy progress by their first scan per literature* P45 Months or Per Pratl 1g /h9 od 8 aha AYBSOO*PocSibjets Largest change in

  12. Slide 12: sAXL/GAS6 Ratio Correlated with Response to Batiraxcept + Chemo

    sAXL/GAS6 Ratio Correlated with Response to Batiraxcept + Chemo sAXL/GASE R. BanaxcePt + PAC (10 & Rae RECUTTS BaCeOT Ts + Serum levels of sAXL/GAS6 ratio (potential biomarker) correlated with response to batiraxcept N 12 7 + Chemo cR 2(17%) ° + Building dataset to understand prognostic ability of b

  13. Slide 13: Promising Responses in Patients > MEC with Poor Prognostic Indicators

    Promising Responses in Patients > MEC with Poor Prognostic Indicators CLINICAL RESPONSE OF Batiraxcept+CHEMO IN CLINICAL RESPONSE OF CHEMOTHERAPY IN PATIENTS PATIENTS WITH <3MO PLATINUMFREE INTERVAL WITH <3MO PLATINUM FREE INTERVAL” (N=21) (N=12) 7 ) = ie be = fon sg i = a 5 & = E 10% = = = ae ‘ORR

  14. Slide 14: Model Informed Drug Development Approach Identified RP2D of 15mg/kg

    Model Informed Drug Development Approach Identified RP2D of 15mg/kg 5/5 patients at 15mg/kg demonstrated clinical benefit: ° tf 4 Complete Response a nal 2 Partial 2 Stable Responses Disease ©2021 Aravive, Inc Traditional MTD or DLT approach for identification of RP2D not appropriate for batiraxcept

  15. Slide 15: Strong Safety Profile of Batiraxcept

    Strong Safety Profile of Batiraxcept 53 PROC Patients Dosed: 10 mg/kg (40); 15 mg/kg (6); and 20 mg/kg (7) + Safety report for trial AVB500-OC-002 generated by independent medical monitor concluded: “Based on a review of the safety data, no unexpected safety trends have been detected and the reporte

  16. Slide 16: Competitive Advantages of Batiraxcept in PROC

    Competitive Advantages of Batiraxcept in PROC: Favorable Safety Profile and Compelling Anti-Tumor Activity + Favorable Safety Profile to Date + NO DLTs like chemotherapies and ADCs + NO dose reductions or discontinuations to manage toxicities + NO toxicities that have been seen with ADCs: neutropeni

  17. Slide 17: Potentially More Favorable Benefit/Risk Profile vs Competitors

    Potentially More Favorable Benefit/Risk Profile vs Competitors Batiraxcept + PAC 10/15mg/kg>MEC N 10 ‘ORR 5 (50%) [PR / CR] [3 PRs (30%); 2 CRs (20%)] sD 3 (30%) PD 2 (20%) ‘mPFS (months) 78 ‘mDOR (months) 74 ‘mOS (months)* 19.0 Discontinuationdue 0 toAES. Dose reductions 0 38/75 13 (34%) / 17 (23%)

  18. Slide 18: Batiraxcept Phase 3 Adaptive Registration Trial Design in PROC

    Batiraxcept Phase 3 Adaptive Registration Trial Design in PROC Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial to Compare Efficacy and Tolerability of Batiraxcept + PAC versus PAC (ClinicalTrials.gov NCT04729608 ) + FDA Feedback: Study could support full approval in * Primary Endpoint: P

  19. Slide 19: Second Indication: Batiraxcept in Clear Cell Renal Cell Carcinoma

    Second Indication: Batiraxcept in Clear Cell Renal Cell Carcinoma; Patients Have Very Poor Survival Rates (e Cell Carcinoma ©2021 Aravive, Inc [%) ‘Sous: NEW CASES and ~13,800 deaths expected in the U.S. in 2021 NEW CASES and ~179,400 deaths worldwide in 2020 1S COMMON 5-YEAR RELATIVE SURVIVAL for m

  20. Slide 20: Strong Biological Rationale for Batiraxcept/Cabozantinib in ccRCC

    Strong Biological Rationale for Batiraxcept/Cabozantinib in ccRCC + GAS6/AXL in clear cell Renal Cell Carcinoma (ccRCC)' a Y AXL plays significant role in ccRCC invasion & metastasis 100 Bic 5 Y AXL highly expressed in aggressive ccRCC tumors and g al h associated with poor outcome Ea a, ¥ GAS6/AXL

  21. Slide 21: Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC

    Batiraxcept + Cabozantinib Phase 1b/2 Trial Design in ccRCC Batiraxcept + Phase 1b Trial of Batiraxcept in Combination Cabo with Cabozantinib spprox. 18) Batiraxcept Dose Levels: + Up to 18 patients; ability to increase/decrease dose aera DL1:15mgikgQ2w based on tolerability, PK/PD DL2 20mg + Histol

  22. Slide 22: Positive Initial Results from the Phase 1b Portion of the Phase 1b/2 Study

    Positive Initial Results from the Phase 1b Portion of the Phase 1b/2 Study Encouraging Pharmacokinetics, Pharmacodynamics and Safety Profile at 15mg/kg of Batiraxcept in combination with Cabozantinib ORR for (60mg) Cabozantinib alone ranges from 17%-27%* * Data in three evaluable patients showed tha

  23. Slide 23: Third Indication: Batiraxcept in Pancreatic Adenocarcinoma

    Third Indication: Batiraxcept in Pancreatic Adenocarcinoma; High Unmet Medical Need to Improve Patient Survival 5-YEAR RELATIVE SURVIVAL Patients with pancreatic cancer have a high mortality rate NEW CASES and ~48,200 deaths expected in the U.S. in 2021 NEW CASES and ~466,000 deaths worldwide in 202

  24. Slide 24: Strong Biological Rationale for Investigating Batiraxcept in Pancreatic Adenocarcinoma

    Strong Biological Rationale for Investigating Batiraxcept in Pancreatic Adenocarcinoma as First-Line Therapy in Combination with Gemcitabine + nab-Paclitaxel (Abraxane®) « Preclinical data demonstrated increased survival in combination with gemcitabine, decreased fibrosis, and decreased tumor weight

  25. Slide 25: Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design

    Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in First-Line Therapy for Advanced or Metastatic Pancreatic Adenocarcinoma Phase 1b Trial of Batiraxcept in Combination with Gemcitabine + nab-Paclitaxel Batiraxcept * Population: Patients (n= approx. 20) with advanced 2 or metastati

  26. Slide 26: Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design

    Batiraxcept + Gemcitabine + nab-Paclitaxel Phase 1b/2 Trial Design in First-Line Therapy for Advanced or Metastatic Pancreatic Adenocarcinoma Planned Controlled, Randomized Phase 2 Trial * Population: Patients (n= approx. 60) with advanced or metastatic pancreatic adenocarcinoma eligible to receive

  27. Slide 27: Development Strategy: Conduct Additional Trials to Expand Pipeline

    Development Strategy: Conduct Additional Trials to Expand Pipeline Preclinical data suggests that batiraxcept has potential in multiple combinations and indications: + Combination trials with agents currently embedded as standard of care + Earlier lines of therapy + Multiple tumor types ©2021 Araviv

  28. Slide 28: Batiraxcept: Large Market Opportunities in PROC, ccRCC, Pancreatic Adenocarcinoma & Other Indications

    Batiraxcept: Large Market Opportunities in PROC, ccRCC, Pancreatic Adenocarcinoma & Other Indications Total Market Ovarian | Renal | Pancreatic | Breast | NSCLC’ | Bladder 2018 $2.38 $3.18 $3.18 $181B $148 $1.68 2028 $0.68 $7.38 $7.38 $4568 $30 $198 Annual Growth Rate 15.6% 9.1% 01% 9.7% 10.8% 28.1%

  29. Slide 29: Strategic Collaborations

    Strategic Collaborations 3DMed Exclusive license agreement for development & commercialization of batiraxcept across alll oncology indications in Greater China + $12M upfront payment received + $207M total potential development and commercial milestone payments; SOM development milestones achieved t

  30. Slide 30: Financial Summary

    Financial Summary | $67.5 million cash and cash equivalents | Achieved two clinical milestones with 3D Medicines, totaling $9 million 20.9 million shares outstanding No debt Cash runway expected to fund base operating plan into 2H 2022 * pataasoraao2e21 ©2021 Aravive, Inc ° 30

  31. Slide 31: Upcoming Key Milestones Advancing Our Clinical Development Program

    Upcoming Key Milestones Advancing Our Clinical Development Program Completion of enrollment in Phase 1b ecRCC trial + Initiation of Phase 2 ecRCC trial ©2021 Aravive, Inc Completion of enrollment in Phase 1b Pancreatic Adenocarcinoma trial + Interim analysis * Initiation of + BLA for PROC for Phase

  32. Slide 32: Advancing Batiraxcept Clinical Trial Program & Pursuing Additional Pipeline Expansion Opportunities

    Advancing Batiraxcept Clinical Trial Program & Pursuing Additional Pipeline Expansion Opportunities Focused on difficult-to-treat cancers: Batiraxcept lead indication in advanced stage ovarian cancer; registrational Phase 3 clinical trial ongoing; ccRCC and pancreatic adenocarcinoma Phase 1b clinica

  33. Slide 33: Experienced Management and Board of Directors

    Experienced Management and Board of Directors Senior Management Hanan A uo cro VP. Regustoy YP, Cinisl Opertons VP, Tanlatonal Medicine Gaumehye, PLD, Reshma Rangwaa, Vinay Shah ody Gould, PRO. “amy Franke, MBE lkabeth Gardiner Ph.D. OagT Board of Directors RG 210HHE cu 4) FP Chan ote Board Oreo nat

  34. Slide 34: Aravive Top Shareholders

    Aravive Top Shareholders Top 10 Shareholders’ Eshelman Ventures (Board member) Invus Public Equities Advisors Tabibiazar, Raymond (Former Board member) New Leaf Venture Partners Giaccia, Amato (Board member) Elite Vantage Global Limited (Board Member) ‘The Vanguard Group Fidelity Management & Resear

  35. Slide 35: Thank you!

    ¢°3 aravive Halting Thank you! Disease Progression in its Tracks S a ©2021 Aravive, nc

  36. Slide 36: Appendix

    ¢°3 aravive Appendix

  37. Slide 37: GAS6 & AXL Expression Associated with Poor Survival in Many Cancers

    GAS6 & AXL Expression Associated with Poor Survival in Many Cancers AXL expressed in >70% of ovarian, pancreatic, breast, kidney, and uterine cancers” “Clinically, the expression of GAS6 and TAM receptors always predicts poor prognosis” Si Gt 1 Mleaarnsightsof Gos6/TAMin concer developmental Cel Dea

Aravive — Investor Presentation (October 2021) on 6ix